Epithelial-Mesenchymal Transition in Cancer: A Historical Overview

Domenico Ribatti *, Roberto Tamma, Tiziana Annese

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy

ARTICLE INFO

Article history:
Received 28 February 2020
Received in revised form 26 March 2020
Accepted 1 April 2020
Available online xxxx

ABSTRACT

Epithelial-mesenchymal transitions (EMTs), the acquisition of mesenchymal features from epithelial cells, occur during some biological processes and are classified into three types: the first type occurs during embryonic development, the second type is associated with adult tissue regeneration, and the third type occurs in cancer progression. EMT occurring during embryonic development in gastrulation, renal development, and the origin and fate of the neural crest is a highly regulated process, while EMT occurring during tumor progression is highly deregulated. EMT allows the solid tumors to become more malignant, increasing their invasiveness and metastatic activity. Secondary tumors frequently maintain the typical histologic characteristics of the primary tumor. These histologic features connecting the secondary metastatic tumors to the primary is due to a process called mesenchymal-epithelial transition (MET). MET has been demonstrated in different mesenchymal tumors and is the expression of the reversibility of EMT. EMT modulation could constitute an approach to avoid metastasis. Some of the targeted small molecules utilized as antiproliferative agents have revealed to inhibit EMT initiation or maintenance because EMT is regulated through signaling pathways for which these molecules have been designed.

© 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Epithelial cell maintains apical-basal polarity and contact with adjacent cells through adherens junctions, tight junctions, and desmosomes. Mesenchymal cells on the other hand are separated with each other by the extracellular matrix, do not have a basal lamina separating them from adjacent tissue, and do not have the distinctive apical-basolateral polarity as epithelial cells.

Greenburg and Hay were the first to show that when epithelial cells derived from embryonic and adult anterior lens were maintained in three-dimensional conditions using a collagen gel culture system, they lose their polarity and acquire mesenchymal properties, and termed this phenomenon “epithelial to mesenchymal transformation” [1]. In 1985, Stocker and Perryman [2] demonstrated that the supernatant derived by fibroblast culture induced the migration of epithelial Madin-Darby canine kidney. In the 1990s, the scattering activity was attributed to the hepatocyte growth factor (HGF).

Epithelial-mesenchymal transitions (EMTs), the acquisition of mesenchymal features from epithelial cells, occur during some biological processes and are classified into three types [3,4]: the first type occurs during embryonic development, the second type is associated with adult tissue regeneration, and the third type occurs in cancer progression. EMT occurring during embryonic development in gastrulation, renal development, and the origin and fate of the neural crest is a highly regulated process, while EMT occurring during tumor progression is highly deregulated.

Biological Mechanisms of EMT

The events occurring during EMT include the loss of adherents junctions and the downregulation of cytokeratins and E-cadherin, epithelial specific markers, and by the increase of mesenchymal markers, such as fibronectin, N-cadherin, and vimentin, the gaining of a fibroblastoid invasive phenotype, as well as the anoikis/apoptosis resistance [5–7]. EMT markers are summarized in Table 1. EMT is modulated through complex molecular pathways that involve microRNAs and epigenetic and posttranslational regulators along with alternative splicing events [8].

Transcription factors including Snail1/Snail, Snail2/Slug, Twist, and ZEB1 are involved in the orchestration of EMT [9]. Snail1-induced EMT involves the loss of E-cadherin and claudins with concomitant upregulation of vimentin and fibronectin, among other biomarkers [10]. Snail2-deficient mice show delayed mammary gland tubule growth and precocious branching morphogenesis [11]. Twist overexpression was correlated with hepatocellular carcinoma metastasis through induction of EMT changes and hepatocellular cell invasiveness [12]. In invasive ductal and lobular breast cancer, upregulation of ZEB1 was coupled to cancer cell...
In addition, vimentin and Snail have also been associated with the malignant phenotype of NSCLC [26,27]. It has been demonstrated that transforming cell-cell adhesion and gain migratory and invasive properties, becoming survival of patients and are characterized by high malignancy grade in during the tumor progression due to EMT. The vast majority of tumors un- decreased expression of E-cadherin influencing grade, local invasiveness, dissemination into the blood, and tumor relapse after therapy [29-31].

In human carcinomas, among the transcription factors involved in EMT, Snail has the major role as inducer, while Twist and Zeb ½ are principally involved in retaining the invasive mesenchymal phenotype [32]. In particular, it was found that Snail 1 is specifically expressed at the invasive front of colon carcinoma. In addition, the Snail 1 expression is correlated both to the malignancy of experimentally induced breast tumors and to an increased possibility of tumor relapse and poor survival in human breast cancer [33]. Vimentin is expressed at high levels in many epithelial tumors, including breast cancer, prostate cancer, melanoma, and lung cancer, and its expression is determinant for tumor growth, invasion, and poor prognosis and serves as potential target for cancer therapy [34]. Overexpression of vimentin in MCF7 cells increased cell stiffness, elevated cell motility and directional migration, reoriented microtubule polarity, and increased EMT phenotypes due to the increased β1-integrin and the loss of junction protein E-cadherin [35]. A relation between hypoxia and β-catenin in human prostate cancer has been found. In this tumor, both the expression and the nuclear activity of β-catenin are associated with the concentration of hypoxia inducible factor 1 alpha (HIF-1α)–induced EMT [36]. This process can also be potentiated by Wnt3a/β-catenin pathway in hepatocellular carcinoma [37].

EMT and Stemness

EMT activation has been associated to the generation of cancer stem cells (CSCs) [38]. Several studies have demonstrated a link between EMT, stemness, and the metastatic initiating potential of tumor cells. Induction of EMT in transformed epithelial cells was shown to culminate in endowing cells with stem-like traits [39,40]. These stem-like traits promoted the initiation of primary tumors and accelerated metastasis [41,42]. For example, EMT-TF Zeb1 promotes stemness and inhibits epithelial differentiation by repressing miR-200 family members [43]. Carcinoma CSCs express at the same time phenotypic characteristics of epithelial and mesenchymal cells, and this allows CSCs to move in alternative states during EMT. Moreover, CSCs are involved in tumor growth, metastatic process, drug resistance, and tumor relapse after therapy. Experimental evidences showed that a subpopulation of CSCs included in a human mammary epithelial cell culture if stimulated by TGF-β or through Snail1/Twist1 inducer undergoes EMT and develops mammospheres [44]. In pancreatic cancer cells, Notch signaling is involved in the acquisition of EMT and cancer stem-like phenotypes [45]. Since the initial discovery of the connection between breast cancer cells that have undergone EMT and their entrance into a stem-cell like state [46], a number of studies have reported acquisition of stemness following the activation of an EMT program in multiple cancer types including pancreatic, prostate, colorectal, and ovarian cancer [47–50]. CCL21/CCL21/CCR7 axis regulated EMT progress and promoted the stemness of oral squamous cell carcinoma by activating the JAK2/STAT3 signaling pathway [51]. A stemness- and EMT-based gene expression signature identifies phenotypic plasticity and is a predictive but not prognostic biomarker for breast cancer [52]. Using different murine pancreatic ductal adenocarcinoma and pancreatitis models, Rhim et al. demonstrated that cells which have undergone a partial EMT and express E-cadherin and Zeb1 exhibit stem cell properties [53]. CD133, a cell surface antigen associated with CSCs in human pancreatic ductal adenocarcinoma, mediates EMT through the regulation of SnaI2 in human pancreatic cells [54].

Overall, these studies demonstrated that EMT, along with the resulting acquisition of stem cell–like properties, facilitates dissemination and consequently the outgrowth of tumor cells at distant organs [55].

EMT and Cytokines

Different cytokines are involved in EMT induction, including HGF, epidermal growth factor (EGF), and fibroblast growth factor (FGF) [56–58]. FGF acts as a chemoattractant for epithelial cells which express FGF receptors, and FGF is able to induce epithelial cell growth. Cancer cells that

### Table 1

**EMT Markers**

| Increased proteins           |
|-----------------------------|
| N-cadherin                  |
| Vimentin                    |
| Fibronectin                 |
| Snail 1 (Snai)              |
| Snail 2 (Slugs)             |
| Twist                      |
| FOX C2                      |
| SOX 10                      |
| MMP-2, MMP-3, MMP-9         |
| N-cadherin                  |

| Decreased proteins          |
|-----------------------------|
| E-cadherin                  |
| Desmoplakin                 |
| Cytokeratin                 |
| Occludin                    |

| Functional markers          |
|-----------------------------|
| Increased migration         |
| Increased invasion          |
| Increased scattering        |
| Elongation of cell shape     |
| Resistance to anoikis       |
undergo EMT secrete cytokines such as TGF-β, interleukin-10 (IL-10), and thrombospondin-1 (TSP-1) that result in a generally immunosuppressive tumor microenvironment [59]. Cytokines such as IL-8, IL-6, and tumor necrosis factor alpha (TNF-α), often secreted by tumor stroma, can also promote EMT [60–62].

In human NSCLC, IL-27 through a STAT1 dominant pathway increases the expression of epithelial markers and inhibits cell migration and the angiogenic activity [63]. Moreover, when lung cancer cells are stimulated with IL-27, they increased the epithelial marker expression (E-cadherin and β-catenin) and reduced the expression of both Snail (transcriptional repressor of E-cadherin) and mesenchymal markers (N-cadherin and vimentin). It has been also observed that IL-27 inhibited in vitro tumor cell migration [65]. The negative effect of IL-6 on E-cadherin expression in breast cancer cell lines was also demonstrated [64]. Sullivan et al. [61] demonstrated that the ectopic expression of IL-6 in MCF7 cells activated the JAK2/STAT3 pathway and Twist, leading to the acquisition of mesenchymal markers and properties.

EMT and Stromal Tumor Cells

Epithelial-mesenchymal interactions within the tumor microenvironment integrate several important signaling molecules that are critical for tumor growth and metastasis, including integrins, cytokines, and growth factors [65]. The presence of cytokines such as HGF, EGF, platelet derived growth factor (PDGF), and TGF-β produced and released by the tumor stroma acts by inducing EMT and favoring processes such as metastasis [66,67], and they can activate a number of transcription factors of genes that promote EMT, such as Snail, Slug, ZEB1, and released by the tumor stroma acts by inducing EMT and favoring processes such as metastasis [65]. The negative effect of IL-6 on E-cadherin expression in breast cancer cell lines was also demonstrated [64]. Sullivan et al. [61] demonstrated that the ectopic expression of IL-6 in MCF7 cells activated the JAK2/STAT3 pathway and Twist, leading to the acquisition of mesenchymal markers and properties.

EMT and Metastasis

Invasion of cells into the extracellular matrix is considered one of the first steps in metastatic cascade. The cells acquiring the ability to migrate and invade matrix have long been considered a hallmark of EMT and have been used as a surrogate to describe the role of EMT in metastasis [73]. Distinct mechanisms are involved including cytoskeletal reorganization, altered expression of cell adhesion molecules, degradation of basement membrane through activation of MMP-2 and MMP-9 [74], as well as sustained autocrine growth factor signaling to evade apoptosis and/or anoikis [75]. Studies using mouse models of breast and skin cancers have demonstrated that activation of an EMT program is important for primary tumor cells to disseminate into the lungs, while the disseminated cells need to subsequently reverse the EMT program and gain epithelial characteristics in order to efficiently form macroscopic metastases [76,77]. In multiple carcinomas, experimental activation of the EMT program results in a remarkable increase in the ability of these cells to extend filopodium-like protrusions, allowing these EMT-activated cells to proliferate following extravasation, ultimately enabling them to seed metastases [78].

EMT and Circulating Tumor Cells (CTCs)

CTCs are constituted by carcinoma cells penetrated into the blood vessels (intravasated) and reaching distant sites where they form new metastatic colonies. CTCs show an incomplete EMT activation and express both epithelial and mesenchymal markers. CTCs are considered as precursors of metastasis, and the molecular attributes of these cells will provide a useful tool to clarify the mechanisms underlying malignant spread. A higher number of mitotic CTCs have been found in advanced metastatic breast cancer patients, and the mitotic state of CTCs correlated with shorter survival in these patients [79]. Mesenchymal CTCs have been found to be higher in patients affected by progressive tumors [80]. The presence of CTCs during primary prostatic cancer has been associated to the alteration of E-cadherin expression [29].

EMT and Tumor Angiogenesis

EMT and angiogenesis are two critical factors influencing tumor growth and metastasis. Angiogenesis is a crucial event in tumor progression and metastasis formation, allowing the transition from an avascular steady state of tumor growth to a vascularized phase through the so-called angiogenic switch. In the promotion of tumorigenesis, EMT and angiogenesis have been revealed as integral processes [81]. It has been demonstrated that levels of vascular endothelial growth factor (VEGF) and EGF receptor (EGFR) are associated with hangs in Twist2 expression and reduction of E-cadherin levels [82]. The activation of VEGF pathways in hypoxic tumors stimulates endothelial mesenchymal transition in angiogenic tumor endothelial cells [83]. The administration of VEGF in xenograft experimental models of preinvasive cells induced the expression of EMT markers [84,85]. VEGF receptor-1 (VEGFR-1) activation results in EMT, tumor cell motility, and invasiveness in human pancreatic carcinoma cells [86]. The cross talk between Notch and VEGF pathways in the context of hypoxic tumors promotes endothelial mesenchymal transition in angiogenic tumor endothelial cells [87]. Studies on xenografts in preinvasive cells demonstrated that the addition of VEGF induces the appearance of EMT markers [88,89].

EMT and Tumor Dormancy

Dormancy of the early disseminated tumor cells may display an EMT/mesenchymal-to-epithelial transition (MET) transient state leaning to a more mesenchymal phenotype, resulting in CSC-like traits responsible for their quiescence. Snail, one of EMT transcription factors, could dramatically impair cell-cycle progression by repressing the transcription of cyclin D2 whose activity was required for cell division [90]. Moreover, Snail could suppress tumor cell proliferation through binding to flanking region of proliferating cell nuclear antigen gene to decrease its expression [91]. However, how these tumor cells remain and exit dormancy has not been verified, and the dynamic changes of the cellular phenotype in tumor progression have not been shown in vivo [53,92]. EMT of dormant MCF7 cells expressing LOXL2 was required for their CSC-like properties and their transition to metastatic outgrowth. Moreover, increase in LOXL2 mRNA levels correlates with increase in the mRNA levels of EMT and stem cells markers, and is also associated with decrease in relapse-free survival of breast cancer patients [93].
EMT and Immune Interactions

The link between EMT and immune recognition and killing of cancer cells is well established. EMT contributes to immune escape of tumors as it has been demonstrated in the human mammary carcinoma model MCF7 which underwent EMT, following stable expression of Snail or after prolonged exposure to TNF-α, and exhibited reduced susceptibility to tumor lymphocytes-mediated lysis [94]. High levels of the EMT-related factor Brachyury reduced the susceptibility of carcinoma cells not only to tumor lymphocytes but also to natural killer (NK) cells, lymphokine-activated killer, FAS, and TRAIL-induced cell death [95]. Exposure to inflammatory cytokines can endow cancer cells undergoing EMT with a number of immunomodulatory effects, including interference with proliferation, differentiation, and apoptosis of NK, T-, and B-cell populations [96]. A correlation between high EMT score and high expression of several immune checkpoints including PD1, PD-L1, PD-L2, B7-H3, OX40, OX40L, CD137, TIM3, LAG3, and CTLA4 has been demonstrated [97]. A CXCL1-LCN2 paracrine network was demonstrated in prostate cancer tissue samples, which was correlated with the recurrence of prostate cancer. CXCL1-LCN2 axis activates Src signaling, triggers the EMT, and promotes the migration of prostate cancer cells, leading to enhanced tumor metastasis [98]. Neuroblastoma MSCs exhibited greater immunosuppressive capacity on activated T lymphocytes compared with bone marrow MSCs, and transcriptomic profiling results indicated that neuroblastoma MSCs were enriched with EMT genes compared to bone marrow MSCs [99]. Analysis of primary tumors from patients with NSCLC revealed a positive correlation among intratumoral macrophage densities, EMT markers, TGF-β levels, and tumor grade [100]. In colon and breast cancer, platelets promote extravasation of cancer cells by inducing EMT through direct contact and release of TGF-β [101]. Various cytokines, including IL4, IL6, IL10, TNF-α, and TGF-β1, secreted by activated macrophages could induce EMT by altering the expression of EMT-related genes in human cholangiocarcinoma [102].

EMT and Senescence

The levels of SPARC allow to distinguish high-grade breast cancer with improved EMT, resistance to treatment, and poor prognosis. The induction of EMT by SPARC is associated to the localization and suppressive function of myeloid cells, and the administration of amino-bisphosphonates could revert EMT through the inhibition of the suppression activity in myeloid-derived stem cells [110].

The identification of the EMT as a common regulator of the CSC phenotype across various carcinoma types has provided us to investigate, at the molecular level, how CSCs and therapeutic resistance are linked via EMT programs. An analysis of responses to chemotherapy in patients with breast cancer revealed a close association between therapeutic resistance and increased expression of genes that are usually expressed primarily by the stromal cells; this transcriptional upregulation seems to be caused by activation of the EMT program within carcinoma cells [111]. In NSCLC and ovarian cancer, the EMT switches the dependence of carcinoma cells from the EGFR to the AXL receptor tyrosine kinase, thereby yielding resistance to EGFR-targeted therapy [112,113]. Moreover, EMT contributes to the establishment of an immunosuppressive tumor microenvironment and thereby confers resistance to immunotherapies [114]. In breast cancer model, mesenchymal cancer cells within a tumor were able to induce the immunosuppressive microenvironment and protect the more epithelial cancer cells residing in the same tumor from immune attack [115].

EMT and Chemo resistance

Two reports provide convincing evidence linking the EMT to cancer drug resistance, particularly favoring the multidrug resistance phenotype but also radioresistance, which may be caused by an enhancement of cancer cell survival, cell fate transition, and/or upregulation of drug resistance-related genes [103,104]. Moreover, the context-dependent stemness of the transformed cells and their mesenchymal status, the dysregulation of particular transcription factors, as well as relevant signaling cascades influencing major antitumor barriers in cells, i.e., senescence and various forms of cell death, might be involved [105–109].

EMT and MET

The identification of EMT as a key factor in cancer progression has led to the study of the process of mesenchymal to epithelial transition (MET). Several studies have demonstrated that EMT and MET can occur in a reversible manner, with MET being induced by the release of TGF-β, leading to the re-expression of E-cadherin and the loss of mesenchymal markers [119]. This process can be regulated by several factors, including SPARC, which has been shown to promote MET by inhibiting EMT [120]. The regulation of EMT and MET is crucial for understanding the heterogeneity of cancer cells and the development of therapeutic strategies.
fibroblasts induces EMT in neighboring epithelial cells and contributes to EMT in nonaggressive human breast cancer cell lines [121].

**EMT and Inflammation**

Inflammatory mediators, including soluble factors, oxidative stress, or hypoxia, can foster the acquisition of EMT-like features in cancer cells [122]. The number of tumor-associated macrophages has been correlated with EMT-like features in gastric cancer [123], NSCLC [72], or head and neck cancer [124]. In hepatocellular carcinoma, macrophages induce EMT in cancer cells in co-culture experiments in an IL-8–dependent fashion [125] or in a TGF-β–dependent fashion [126,127]. The induction of EMT by TNF-α, in synergy with TGF-β or other inflammatory factors, has been described [128]. The link between IL-8 and EMT has established a form of a mutual loop in which IL-8 and EMT programs sustain each other in tumor microenvironment [129]. EMT in association with inflammation has also been correlated with higher stages of cancer progression. In patients with inflammatory breast cancer, a correlation exists between immune activation and the presence of circulating tumor cells with EMT characteristics [130].

**Mesenchymal-Epithelial Transition**

Following the metastatic tumor cells arriving at distant sites, they undergo MET, reversing the conversion into metastatic lesions [21]. Multiple transition states have been demonstrated in tumors, suggesting that the tumor cells could frequently express a mix of both epithelial and mesenchymal genes [131]. The histologic features connecting the secondary metastatic tumors to the primary is due to a process called MET that allows the cancer tumor cells to colonize secondary distant sites (Figure 1). MET has been demonstrated in different mesenchymal tumors and is expression of the reversibility of EMT [132]. Comparing expression of epithelial junctional proteins including E-cadherin, β-catenin, and connexin in primary tumor and matched distant metastases in lung, liver, and brain of cancer patients shows equal or increased epithelial cells in metastases, indicating that circulating mesenchymal tumor cells undergo MET [133]. However, the exact mechanisms underlying MET, including where and how MET takes place and how it facilitates the formation of metastases, remain largely elusive, and compared to EMT, molecular mechanisms mediating MET are relatively less characterized [134,135]. GRHL2, a transcription factor that activates E-cadherin and Claudin-4, and OVOL1/2 can repress EMT-associated transcription factors and drive MET [136–138]. However, the overexpression of OVOL2, GRHL2, or E-cadherin may not always be sufficient to drive complete MET [139–142].

**Concluding Remarks and Future Perspectives**

EMT is of extreme importance in tumor microenvironment in the regulation of tumor growth, progression, and metastatic cascade. Context-dependent signaling transduction pathways and microenvironment signals, such as hypoxia, oxidative stress, nutrient deprivation, or inflammation, and EMT transcription factors such as Snail1/Snail2, ZEB1/ZEB2, and Twist1 are responsible to induce and sustain the mesenchymal phenotype (Figure 2).

The EMT process within the tumor context is highly dynamic, implying transient and reversible states, thus resembling embryonic development where EMT and the reverse MET processes occur as necessary steps for early embryogenesis and morphogenesis. EMT stimulates the tumor angiogenesis, but the role of EMT on the interaction between tumor cells and the tumor microenvironment has not been deepened even though the mechanisms inducing EMT and their
association to improved invasive properties of tumor cells have been extensively studied. The induction of EMT confers therapy resistance in tumor cells [143] that leads to a reduction of proliferation rate and increased expression of both antiapoptotic proteins and transporters belonging to ATP binding cassette that are responsible of drug efflux. EMT has a role in the establishment of an immunosuppressive tumor microenvironment and induces also immunotherapies resistance. In this context, an increased immunosuppressive regulatory T cells infiltration in tumor microenvironment when EMT is stimulated by Snail in melanoma cells was found [144].

Intermediate states between epithelial and mesenchymal phenotypes might occur at different steps of the metastatic cascade with cells transitioning through hybrid states during tumor dissemination. EMT modulation could constitute an approach to avoid metastasis. For example, some of the targeted small molecules utilized as antiangiogenic agents have been revealed to inhibit EMT initiation or maintenance because EMT is regulated through signaling pathways for which these molecules have been designed [145]. The modulation of the signaling processes involved in inducing and maintaining mesenchymal characteristics can inhibit EMT. Experimental works established that extracellular vesicles, including exosomes, play a role in EMT and metastasis [146–148]. Thus, exosomes are considered as potential doxorubicin delivery system for tumor tissue to inhibit tumor growth with a reduced toxicity [149].

One of the challenges is the characterization of a number of genes or proteins that could be studied in human samples to predict the establishment or acquisition of EMT or hybrid states, along with the detection of the reverse MET process. These specific signatures could be used as new tools for understanding tumor cell plasticity as well as for diagnosis and prognosis. Additional studies using innovative genetically engineered animal models to trace and analyze tumor cells responsible for seed metastasis, together with higher-resolution in vivo intravital imaging microscopy, would contribute to better understand the biological relevance of EMT and plasticity processes to metastasis in different tumors. Finally, the emergence of targeted therapies against signaling regulators of EMT might lead toward clinical benefits due to the specific targeting of cancer cells undergoing EMT.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by the European Union Seventh Framework Program OPTATIO (PFP7/2007-2013) under grant agreement n°278570.

References

[1] G. Greenburg, E.D. Hay, Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells, J Cell Biol 95 (1) (1982) 333–339, https://doi.org/10.1083/jcb.95.1.333.
[2] M. Stoker, M. Perryman, An epithelial scatter factor released by embryo fibroblasts, J Cell Sci 77 (1985) 209–225.
[3] R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition, J Clin Invest 119 (6) (2009) 1420–1428, https://doi.org/10.1172/JCI39104.
[4] M. Zeisberg, E.G. Neilson, Biomarkers for epithelial-mesenchymal transitions, Journal of Cellular Physiology 213 (2) (2007) 374–381, https://doi.org/10.1002/jcp.21223.
[5] T.K. Lee, R.T.P. Poon, A.P. Yuen, M.T. Ling, W.K. Kwok, X.H. Wang, et al., Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition, Clin Cancer Res 12 (18) (2006) 5369–5376, https://doi.org/10.1158/1078-0432.CCR-05-2722.
[6] K. Chu, K.M. Boley, R. Moraes, S.H. Barsky, F.M. Robertson, The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism, Oncotarget 4 (3) (2013) https://doi.org/10.18632/oncotarget.872.
[7] M.W. Klymowski, β-catenin and its regulatory network, Human Pathology 36 (3) (2005) 225–227, https://doi.org/10.1016/j.humpath.2005.02.002.
[8] S. Kase, K. Sugio, K. Yamazaki, T. Okamoto, T. Koga, K. Ondo, et al., Expression of E-cadherin and β-catenin in human non-small cell lung cancer: clinical significance, Cancer Science 100 (9) (2009) 1671–1676, https://doi.org/10.1111/j.1349-7006.2009.01331.x.
[9] K. Aigner, B. Dampier, L. Descovich, M. Mikula, A. Sultan, M. Schreiber, et al., The paradox of E-cadherin: repressing master regulators of epithelial polarity, Oncogene 26 (49) (2007) 6979–6988, https://doi.org/10.1038/onc.2007.105.
[10] L. Thompson, B. Chang, S.H. Barsky, Monoclonal origins of malignant mixed tumors (carcinosarcomas), The American Journal of Surgical Pathology 20 (3) (1996) 227–285, https://doi.org/10.1097/00000478-199606000-00003.
[11] J. Xu, S. Lamouille, R. Derynck, TGF-β-induced epithelial to mesenchymal transition, Cell Research 19 (2) (2009) 156–172, https://doi.org/10.1038/cr.2009.5.
[12] T.K. Lee, R.T.P. Poon, A.P. Yuen, M.T. Ling, W.K. Kwok, X.H. Wang, et al., Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition in the epiblast, Development 131 (23) (2004) 5817–5824, https://doi.org/10.1242/dev.01453.
[13] J.P. Thiery, H. Acrour, R.Y. Huang, M.A. Nieto, Epithelial-mesenchymal transition in development and disease, Cell 139 (5) (2009) 671–686, https://doi.org/10.1016/j.cell.2009.11.007.
[14] L. Thompson, B. Chang, S.H. Barsky, Monoclonal origins of malignant mixed tumors (carcinosarcomas), The American Journal of Surgical Pathology 20 (3) (1996) 227–285, https://doi.org/10.1097/00000478-199606000-00003.
neoplasia (PIN)-like cells via an autocrine loop, Experimental Cell Research 316 (4) (2020) 5701–5707, https://doi.org/10.1016/j.yexcr.2020.05.029.

94. A.D. Yang, E.R. Camp, F. Pan, L. Shen, M.J. Gray, W. Liu, et al., Epithelial-mesenchymal transition traits in human breast cancer cell lines, Clin Exp Metastasis 22 (7) (2004) 472–480, https://doi.org/10.1023/B:CEMT.0000035163.81067.8c.

95. Q.M. Fan, Y.Y. Jing, G.F. Yu, X.R. Kou, F. Ye, L. Gao, et al., Tumor-associated macrophages promote epithelial-mesenchymal transition in hepatocellular carcinoma, Oncotarget 7 (25) (2016) 39823–39832, https://doi.org/10.18632/ott.201605.0291.

96. X. Long, Y. Ye, L. Zhang, J.H. Li, H.Y. Qu, et al., IL-8 induces epithelial-to-mesenchymal transition in oral squamous cell carcinoma, J Exp Clin Cancer Res 35 (2016) 12, https://doi.org/10.1186/s13048-015-0286.

97. S. Yuan, J.J. Chen, P.Y. Cao, P. Sun, The role of interleukin-8 in cancer cells and microenvironment interaction, Front Biosci 10 (2005) 853–860, https://doi.org/10.2741/119.

98. R.C. Bates, A.M. Mercurio, The epithelial-mesenchymal transition (EMT) and colorectal cancer progression, Cancer Biol Ther 4 (4) (2005) 365–370, https://doi.org/10.4161/cbt.4.4.4184, https://doi.org/10.1158/0008-5472.CAN-09-4614.

99. R.C. Bates, A.M. Mercurio, Macrophage-secreted tumor-associated cytokines released from activated human macrophages induce epithelial-mesenchymal transitions in cancer, Cancer Res 72 (19) (2012) 4883–4891, https://doi.org/10.1158/0008-5472.CAN-12-0548.

100. C.C. Hughes, Crosstalk between vascular endothelial growth factor, tumor necrosis factor-a and interleukin-8, Oncogene 24 (2005) 8190–8198, https://doi.org/10.1038/sj.onc.1209134.

101. J. Yuan, J.J. Chen, P.Y. Cao, P. Sun, Macrophage-secreted tumor-associated cytokines promote invasion of prostate cancer via a recombinant brachyury-yeast vaccine, Oncotarget 7 (2016) 1176–1186, https://doi.org/10.18632/ott.2015.29.

102. M. Ansieau, J. Bastid, A. Doroae, A. P. Morel, B. P. Bouclet, C. Thomas, et al., Induction of epithelial-to-mesenchymal transition, Cancer Cell 14 (1) (2008) 79–89, https://doi.org/10.1016/j.cancert.2008.04.016.

103. H.Y. Yan, Y. El-Naggar, L.J. Higuchi, J.A. Dean, EMT marks epithelial-mesenchymal transition and cellular senescence, Development 135 (3) (2008) 579–588, https://doi.org/10.1242/dev.007047.

104. S. Ohashi, M. Natsukiza, G.S. Wong, C.Z. Michaylin, K.O. Gregan, D.B. Stains, et al., Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors, Cancer Res 70 (10) (2010) 4174–4184, https://doi.org/10.1158/0008-5472.CAN-09-4614.

105. J.P. Coppe, C.K. Fatib, F. Rodier, Y. Sun, D.P. Munro, J. Goldstein, et al., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor, PLoS Biol 6 (12) (2008) 2853–2868, https://doi.org/10.1371/journal.pbio.0060301.

106. A. Yuan, J.J. Chen, P.Y. Cao, P. Sun, The role of interleukin-8 in cancer cells and microenvironment interaction, Front Biosci 10 (2005) 853–865, https://doi.org/10.2741/119.

107. R.M. Laberge, P. Awad, J. Campi, P.Y. Desprez, Epithelial-mesenchymal transition induced by senescent fibroblasts, Cancer Microenvriron 5 (1) (2012) 39–44, https://doi.org/10.4155/cme.11.50.

108. J.M. Lopez-Novoa, M.A. Nieto, Inflammation and EMT: an alliance towards organ fibrosis and cancer progression, EMBO Mol Med 1 (67) (2009) 303–314, https://doi.org/10.1002/emm.200900403.

109. Y. Li, X. Ding, Y. Zhang, J.H. Li, X. Wang, H.Y. Qu, et al., High tumor-associated macrophages infiltration is associated with poor prognosis and may contribute to the phenomenon of epithelial-mesenchymal transition in gastric cancer, Onco Targets Ther 9 (2016) 3975–3983, https://doi.org/10.2147/OTT.S9749.

110. Y. Hu, M.T. He, L.P. Zhou, X. Yin, Q. Wang, et al., Macrophage-secreted cytokines correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma, J Exp Clin Cancer Res 35 (2016) 12, https://doi.org/10.1186/s13048-015-0286.

111. X.T. Fu, Z. Dai, K. Song, Z.J. Zhang, Z.J. Zhou, S.L. Zhou, et al., Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway, Int J Oncol 48 (6) (2016) 2545–2551, https://doi.org/10.3892/ijo.2016.3883.

112. R.A. Yang, W.B. Liu, Z.X. Lian, X. Li, X. Hou, Sofarinib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma, Oncotarget 7 (25) (2016) 38829–38830, https://doi.org/10.18632/ott.209438.

113. Q.L. Liu, Y.Y. Jing, G.F. Yu, X.R. Kou, F. Ye, L. Gao, et al., Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta induces epithelial-mesenchymal transition in hepatocellular carcinoma, Cancer Lett 325 (2) (2014) 160–168, https://doi.org/10.1016/j.canlet.2014.05.008.

114. R.C. Bates, A.M. Mercurio, The epithelial-mesenchymal transition (EMT) and cervical cancer progression, Cancer Biol Ther 4 (4) (2005) 365–370, https://doi.org/10.4161/cbt.4.4.1655.

115. X. Long, Y. Ye, L. Zhang, P. Liu, W. Fu, et al., IL-8, a novel messenger to cross-talk inflammatory autocrine and paracrine pathways, Int J Oncol 48 (1) (2016) 5–12, https://doi.org/10.3892/ijo.2015.3234.

116. E.N. Cohen, H. Gao, S. Anfossi, M. Megu, N.G. Reddy, B. Debe, et al., Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells, Oncotarget 10 (7) (2015) 60127–60130, https://doi.org/10.18632/oncotarget.5417.

117. M.A. Nieto, Ruby-J. Y. Huang, Rebecca A. Jackson, Jean P. Thiery, EMT: 2016, Cell 166 (1) (2016) 21–45, https://doi.org/10.1016/j.cell.2016.06.028.

118. J.P. Thiery, Epithelial-Mesenchymal transition, Nature Reviews Cancer 2 (6) (2002) 442–454, https://doi.org/10.1038/nrc822.
Y. Chao, Q. Wu, M. Acquafondata, R. Ibir, A. Wells, Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases, Cancer Microenviron 5 (1) (2012) 19–28, https://doi.org/10.1007/s12307-011-0085-4.

D. Pei, X. Shu, A. Gassama-Diagne, J.P. Thiery, Mesenchymal-epithelial transition in development and reprogramming, Nat Cell Biol 21 (1) (2019) 44–53, https://doi.org/10.1038/s41556-018-0195-x.

D. Yao, C. Dai, S. Peng, Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation, Mol Cancer Res 9 (12) (2011) 1608–1620, https://doi.org/10.1158/1541-7786.MCR-10-0568.

V.Y. Chung, T.Z. Tan, M. Tan, M.K. Wong, K.T. Kuoy, Z. Yang, et al., GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification, Sci Rep 6 (2016) 19943, https://doi.org/10.1038/srep19943.

S.M. Frisch, J.C. Farris, P.M. Pifer, Roles of Grainyhead-like transcription factors in cancer, Oncogene 36 (44) (2017) 6067–6073, https://doi.org/10.1038/onc.2017.178.

H. Roca, J. Hernandez, S. Weidner, R.C. McElhin, D. Fuller, S. Sud, et al., Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer, PLoS One 8 (10) (2013), e76773. https://doi.org/10.1371/journal.pone.0076773.

V.Y. Chung, T.Z. Tan, J. Ye, R.L. Huang, H.C. Lai, D. Kappei, et al., The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells, Commun Biol 2 (2019) 272, https://doi.org/10.1038/s42003-019-0506-3.

M.K. Jolly, K.E. Ware, S. Xu, S. Gilja, S. Shetler, Y. Yang, et al., E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms, Mol Cancer Res 17 (6) (2019) 1391–1402, https://doi.org/10.1158/1541-7786.MCR-18-0763.

X.K. Qi, H.Q. Han, H.J. Zhang, M. Xu, L. Li, L. Chen, et al., OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma, Theranostics 8 (8) (2018) 2202–2216, https://doi.org/10.7150/thno.24003.

J.A. Somarelli, S. Shetler, M.K. Jolly, X. Wang, S. Bartholf Dewitt, A.J. Hish, et al., Mesenchymal-epithelial transition in sarcomas is controlled by the combinatorial expression of microRNA 200s and GRHL2, Mol Cell Biol 36 (19) (2016) 2503–2513, https://doi.org/10.1128/MCB.00573-16.

T. Shibue, R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, Nature Reviews Clinical Oncology 14 (10) (2017) 611–629, https://doi.org/10.1038/nrclinonc.2017.44.

J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial–mesenchymal transitions, Nature Reviews Molecular Cell Biology 7 (2) (2006) 131–142, https://doi.org/10.1038/nrm1835.

B. dos Anjos Pultz, F. André Cordero da Luz, S. Socorro Faria, L. Peixoto Ferreira de Souza, P. Cristina Brígido Tavares, V. Alonso Goulart, et al., The multifaceted role of extracellular vesicles in metastasis: priming the soil for seeding, International Journal of Cancer 140 (11) (2017) 2397–2407, https://doi.org/10.1002/ijc.30595.

J. Kim, T.Y. Kim, M.S. Lee, J.Y. Mun, C. Ihm, S.A. Kim, Exosome cargo reflects TGF-β1-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells, Biochemical and Biophysical Research Communications 478 (2) (2016) 643–648, https://doi.org/10.1016/j.bbrc.2016.07.124.

Wang, Z., von Au, A., Schmülling, M., Hackert, T., and Zöller, M. (2016). CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget 7(34). doi: 10.18632/oncotarget.15580.

Y. Tian, S. Li, J. Song, T. Ji, M. Zhu, G.J. Anderson, et al., A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials 35 (7) (2014) 2383–2390, https://doi.org/10.1016/j.biomaterials.2013.11.083.